Get the best of CNBC in your inbox
Shares of Canada's Tekmira Pharmaceuticals soared in premarket trading Wednesday on prospects for its Ebola treatment. So did, Massachusetts-based Sarepta Therapeutics.
Jim Russell, U.S. Bank Wealth Management, and James Liu, J.P. Morgan Funds, provide perspective on what's driving the market higher and look ahead to fourth quarter expectations.
Pro-democracy protesters defied calls by Beijing to disperse, reports CNBC's Susan Li, with the latest details on the Hong Kong uprising.
The traveler from Liberia is the first Ebola patient diagnosed in the U.S., reports CNBC's Meg Tirrell.
Robert Reffkin, Urban Compass founder & CEO, talks about building his business in New York and the company's plans to expand into other locations.
David Strauss, UBS aerospace & defense analyst, discusses his "sell" rating and $157 price target on shares of Lockheed Martin.
Antoine Halff, Head, Oil Industry & Markets at International Energy Agency, outlines the factors that are weighing on oil demand around the world.
Speaking to CNBC at the "Russia Calling Conference" in Moscow, Maxim Basov, CEO of Rusagro, explains how the firm has benefited from geopolitical tensions.
Shusuke Yamada, FX strategist at Bank of America Merrill Lynch, discusses Wednesday's Bank of Japan Tankan survey and explains his year-end target of 108 for the dollar-yen.
Lindsey Piegza, chief economist at Sterne Agee, says U.S. markets are "holding their breath" for Friday's jobs report to see if the loss of momentum will continue.
Brian Reynolds, chief market strategist at Rosenblatt Securities, discusses the threat of deflation and says that with U.S. inflation expectations "plunging", it's difficult to see how the Fed "can tighten".
Natalie Berg, grocery research director at Planetretail, comments on U.K. supermarkets - such as Sainsbury's and Tesco - and says the challenge for Tesco is that they're not "sure what they're about".